Sodium-glucose cotransporter 2 (SGLT2)

Overview

Sodium-glucose cotransporter 2 (SGLT2) is a membrane transport protein that mediates glucose reabsorption in the kidney and is a major pharmacologic target in type 2 diabetes. In clinical practice, SGLT2 is most widely discussed in the context of SGLT2 inhibitors, a drug class that reduces renal glucose reuptake and thereby lowers blood glucose. Beyond glycemic control, this target has become important in cardiovascular disease, chronic kidney disease, and heart failure, reflecting a broader therapeutic role than originally recognized.

Biologically, SGLT2 is central to renal glucose handling and is therefore linked to metabolic and hemodynamic effects that extend into multiple organ systems. Recent research has examined SGLT2-targeting therapies in type 2 diabetes, metabolic dysfunction–associated steatotic liver disease, coronary flow and blood pressure regulation, kidney outcomes, and even experimental neuroprotection. Studies have also explored mechanistic associations with oxidative stress, inflammation, neuroprotection, and metabolic remodeling, including interactions with acetylcholinesterase (AChE), superoxide dismutase (SOD), interleukin-1β (IL-1β), and ketone body metabolism.

Recent Publications Summary

Recent studies of sodium-glucose cotransporter 2 (SGLT2) focused on its role as a therapeutic target across kidney, cardiovascular, metabolic, and neurologic contexts. In youth with type 1 diabetes and hyperfiltration, dapagliflozin was tested in a placebo-controlled trial with sequential kidney biopsies, multiparametric kidney MRI, and plasma/urine proteomics; single-cell RNA sequencing showed coordinated transcriptional changes across nephron, vascular, and immune compartments, with proximal tubule downregulation of glycolysis, gluconeogenesis, and oxidative stress markers, endothelial reductions in profibrotic and inflammatory gene expression, and podocyte cytoskeletal reinforcement 42485434Jul. In South Indian patients with type 2 diabetes inadequately controlled on metformin and glimepiride, add-on SGLT2 inhibitor therapy with dapagliflozin or empagliflozin was evaluated in a 24-week prospective observational cohort for glycaemic, anthropometric, haemodynamic, hepatorenal, and mechanistic effects 42449436Jul.

Several publications examined cardiorenal outcomes and comparative effectiveness in type 2 diabetes. A nationwide emulated target trial in Taiwan compared SGLT2 inhibitor users with non-users to assess incident chronic kidney disease, cardiovascular events, and mortality in patients without preexisting CKD 42002149Apr. Another emulated target trial compared individual SGLT2 inhibitors for cardiovascular outcomes in adults with type 2 diabetes and moderate cardiovascular risk, addressing the lack of direct head-to-head comparisons 42132163May. A review of primary care implementation highlighted that SGLT2 inhibitors have become cornerstone therapies for cardiovascular disease, chronic kidney disease, and heart failure, but uptake in UK primary care remains low despite guideline recommendations 42134923May. In heart failure with ischemic cause, investigators also explored whether baseline ketone body metabolism might help explain variability in response to SGLT2 inhibitors using metabolomics integrated with population data across diverse genetic backgrounds 42261991Jun.

Other studies extended SGLT2 inhibitor research to metabolic and vascular phenotypes beyond glucose lowering. In patients with type 2 diabetes and metabolic-dysfunction associated steatotic liver disease, dapagliflozin and dulaglutide were studied for effects on blood pressure and coronary flow 42201656May. In mice fed a high-fat diet, dapagliflozin altered plasma N-glycome profiles in a time-of-day-dependent manner, with nighttime dosing normalizing several diet-induced glycan changes despite limited effects on blood glucose or body weight 41948954Apr. A separate clinical and rodent study reported limited overall impact of SGLT2 inhibitors on appetite and body weight, while another in silico and in vivo investigation suggested that empagliflozin and dapagliflozin may improve cognitive dysfunction in diabetic models, with analyses involving SGLT1, SGLT2, acetylcholinesterase, superoxide dismutase, RAGE, and interleukin-1β 42117145May41819428Mar.

Preclinical work also examined non-metabolic protective effects of dapagliflozin. In rats, dapagliflozin pretreatment attenuated focal cerebral ischemia-reperfusion injury, supporting possible neuroprotective actions of SGLT2 inhibition in a non-diabetic setting 42334656Jun.

What Changes, What Holds

1. Kidney-level mechanistic effects now extend beyond glucose lowering into coordinated nephron, vascular, and immune remodeling
NEW DIRECTION dapagliflozin in youth with type 1 diabetes and hyperfiltration suggests SGLT2 inhibition may act on kidney biology more broadly than the Overview’s renal glucose reabsorption framing implies, with transcriptional and imaging signals pointing to proximal tubule metabolic suppression, endothelial anti-inflammatory/profibrotic effects, and podocyte stabilization 42485434Jul. The add-on cohort in type 2 diabetes also supports broader metabolic and hepatorenal effects, but the main change is mechanistic depth rather than a reversal of the established target role 42449436Jul.

2. Comparative and implementation data make SGLT2 inhibitors look more like a class with variable real-world uptake than a single uniform intervention
REINFORCES These studies strengthen the already established cardiorenal importance of SGLT2 inhibition by showing continued benefit questions around incident CKD, cardiovascular events, mortality, and within-class differences in moderate-risk type 2 diabetes 42002149Apr42132163May. The primary-care review does not change the biology, but it sharpens the gap between guideline status and actual use, while the ketone-metabolism work suggests response heterogeneity that remains hypothesis-generating 42134923May42261991Jun.

3. Effects on vascular, glycomic, appetite, and cognitive phenotypes broaden the target’s footprint beyond glycemic control
NEW DIRECTION dapagliflozin and dulaglutide data in metabolic-dysfunction associated steatotic liver disease, along with the glycome and appetite studies, move SGLT2 research into systemic metabolic regulation rather than simple glucose lowering, which the Overview does not yet cover 42201656May41948954Apr. The cognitive findings are especially notable because they suggest possible neurobehavioral benefit, but they remain preclinical and mechanistically mixed, so they extend the account without settling a new clinical role 42117145May41819428Mar.

4. Neuroprotection emerges as a plausible off-target benefit, but only as early preclinical evidence
NEW DIRECTION dapagliflozin pretreatment reducing ischemia-reperfusion injury in rats adds a non-diabetic neurologic protective direction that is absent from the Overview’s current therapeutic framing 42334656Jun. This does not displace the renal-glucose mechanism; it instead suggests that SGLT2 inhibition may have tissue-protective properties beyond metabolism, though replication and human data would be needed before this could be treated as established 42334656Jun.

Overview update candidates: kidney transcriptomic and imaging evidence for broader renal remodeling; possible neuroprotective actions; broader systemic metabolic/vascular effects beyond glucose lowering.